Retrospective Study Correlation Between Grade and Amount of Mitosis With Er, Pr, and Her2 Expression in Invasive Breast Carcinoma of No Special Type

Kristian, Rebecca Agustine; Sandhika, Willy

doi:10.47119/ijrp1008911120212468

Cited by 2 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HER-2 having no correlation with the degree of histological differentiation of cancer cells means that HER-2 can be possessed by breast cancer cells with varying degrees of malignancy (Kristian & Sandhika, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…The results of multivariate cox regression analysis showed that comorbidities/complications were not a signi cant factor affecting survival. A study by Kristian & Sandhika (2021), concluded that the increased degree of differentiation in cancer cells (grade) would be followed by a decrease in estrogen receptors and progesterone receptors in cancer cells, but there was no correlation between HER-2 examination results and the degree of histological differentiation of breast cancer cells. This shows that lower grade cancer cells have properties that are more similar to normal cells: they have estrogen and progesterone receptors and thus have lower cell growth rates compared to higher grade breast cancers that lose estrogen and progesterone receptors.…”

Section: Discussionmentioning

confidence: 99%

“…Breast cancer cells with a positive HER-2 test result will be sensitive to anti-HER-2 monoclonal antibody therapy. In addition, it also has a high cell proliferation rate so that the cancer is more sensitive to chemotherapy(Kristian & Sandhika, 2021;…”

mentioning

confidence: 99%

“…ER/PR positive cancer cells are sensitive to the presence of the hormones estrogen and progesterone. Cancer cells of this type are sensitive to hormonal therapy and have better cure rates compared to cancer cells that have neither estrogen receptors nor progesterone receptors(Kristian & Sandhika, 2021). Breast cancer cells with a positive HER-2 test result will be sensitive to anti-HER-2 monoclonal antibody therapy.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Yulistiani,

Utomo,

Romadhon

et al. 2024

Preprint

View full text Add to dashboard Cite

Breast cancer in Indonesia is among the first with the highest number of new cancer cases with the second mortality in cancer after lung cancer in 2020. Anthracycline-taxane based regimens and taxane-based regimens are often breast cancer chemotherapy modalities that can support increased patient survival. Side effects occur more frequently in combination regimens. The selection of the right regimen is expected to support the improvement of patient survival. This study aims to analyze the survival rate of chemotherapy regimen groups and hazard ratio factors that are thought to affect survival in breast cancer patients. This study used an observational and retrospective cohort method. The statistical analyzes used in this study include Kaplan-Meier analysis to measure survival rates, Log-rank test to observe the differences between regimen groups and Cox proportional hazards regression to analyze factors that influence survival. Patients who were included in the inclusion and exclusion criteria were 71 patients, consisting of 47 patients who received anthracycline-taxane based combination and 24 patients who received taxane-based chemotherapy. The percentage of one-year and two-year survival in the anthracycline-taxane based combination was 93.6% and taxane-based 83.3% (p>0.05). Multivariate analysis showed that stage increased risk 9 times based on hazard ratio values obtained from cox regression tests (HR 9.60; 95% CI 1.60-57.54; p<0.05). Another significant factor in the multivariate analysis was that delaying chemotherapy increased the risk of survival 5 times (HR 5,58; CI 95% 1.12-27.85 ; p<0.05). Based on research, it can be concluded that anthracycline-taxane based and taxane based combination regimens can be used as a treatment modality for breast cancer patients in both early and advanced stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Yulistiani,

Utomo,

Romadhon

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The expression of ER/PR in each breast cancer cell generally varies, so the response in each patient will be different. The higher expression of ER/PR in cancer cells, the better prognosis the patient has [6].…”

Section: Introductionmentioning

confidence: 99%

Nuclear anaplasia of positive and negative hormonal receptor (estrogen and progesterone receptor) in breast cancer cytology

Nabila Aliya Rahmah Vansya,

Willy Sandhika,

Desak Gede Agung Suprabawati

2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Background: Breast epithelial duct cells show response to sex hormone such as estrogen and progesterone since they have receptor for estrogen and progesterone. Consequently, malignant cells from breast epithelial ductuli (Breast Ductal Carcinoma) show positivity for estrogen and progesterone receptor (ER and PR). However, when this neoplasm becomes poorly differentiated, they lost these characteristics and became ER and PR negative. On the other hand, poorly differentiated cancer cells show more nuclear enlargement that was accompanied by increase nuclear pleomorphism. This study wants to compare area of breast cancer cells nuclei and nuclear pleiomorphism in positive and negative ER and PR. Material and method: Positive and negative ER and PR breast cancer cases were collected from archive of Anatomic Pathology Department each consisting of ten to fourteen cases. Image analysis was made from each case to measure the area, diameter, and nuclear pleiomorphism. Result and discussion: There were no differences in nuclear size and pleomorphism of breast cancer cells with positive and negative ER and PR. This result show that poorly differentiated cancer cells did not accompany by increase of nuclear anaplasia. Conclusion: There is no difference of cancer cells morphology in positive and negative ER and PR. Hormonal status and anaplasia of cell nuclei can be used as independent prognostic factor to breast cancer progression.

show abstract

Retrospective Study Correlation Between Grade and Amount of Mitosis With Er, Pr, and Her2 Expression in Invasive Breast Carcinoma of No Special Type

Abstract: Background:In 2018 there were about 24.2% new cases of breast carcinoma worldwide. Molecular breast carcinoma, like expression estrogen receptor (ER), progesterone receptor (PR),

Cited by 2 publications

References 16 publications

Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Nuclear anaplasia of positive and negative hormonal receptor (estrogen and progesterone receptor) in breast cancer cytology

Contact Info

Product

Resources

About